Morphic Holding, Inc. stock is up 18.33% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 1 PUT, 1 CALL.
Morphic Holding, Inc. discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the. treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis. and fibrosis diseases. The company is also developing avß6 and avß8 to treat solid tumors.